Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

NCT03045328 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Small Lymphocytic Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: Venetoclax

Sponsor

Steven E. Coutre